MFAP4-Targeted Fibrosis Treatment Through Integrin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis, such as liver cirrhosis and idiopathic pulmonary fibrosis, are limited and often associated with adverse side effects, and there are no effective compounds to reverse the excessive deposition of extracellular matrix components that lead to tissue dysfunction.
Innovation Solution
The use of selective targeting agents, including antibodies and fragments, that bind to MFAP4 to inhibit its interaction with integrins, thereby reducing collagen synthesis and reversing the fibrotic process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct inhibition of the TGF- pathway is used to treat fibrosis, then fibrosis treatment is attempted, but unfavorable risk-benefit profiles and adverse side effects result
Solution Approach 1:
The patent extracts and targets a specific component (MFAP4) within the broader TGF- pathway, rather than inhibiting the entire pathway. This selective extraction allows treatment of fibrosis while avoiding the adverse side effects associated with broad TGF- pathway inhibition, as MFAP4 is specifically involved in ECM organization and fibrosis progression
Solution Approach 2:
The patent uses selective targeting agents (antibodies or fragments) as intermediaries to specifically bind and inhibit MFAP4. This intermediary approach allows precise modulation of MFAP4-integrin interactions without the need for direct TGF- pathway inhibition, thereby achieving fibrosis treatment with improved safety profiles
2Duration of action of stationary object
If existing fibrosis drugs (Pirfenidone and Nintedanib) are used, then fibrosis progression is slowed, but they provide no cure and do not reverse fibrosis
Solution Approach 1:
Instead of merely slowing fibrosis progression as existing drugs do, the patent employs selective targeting agents that actively reverse the fibrotic process by de-differentiating myofibroblasts and reducing collagen synthesis. This inverted approach transforms the therapeutic goal from progression control to active reversal and potential cure of fibrosis
Solution Approach 2:
The patent changes the therapeutic parameter from progressive inhibition (slowing fibrosis) to regenerative reversal (de-differentiation of myofibroblasts and reduction of collagen synthesis). By targeting MFAP4 specifically, the treatment modifies the fibrotic state parameters to promote tissue regeneration and reverse established fibrosis
3Adaptability or versatility
If MFAP4-deficient mice are studied, then contradictory results are obtained regarding fibrosis development, indicating complex interaction between MFAP4 and fibrosis
Solution Approach 1:
The patent applies selective targeting to specifically inhibit MFAP4-integrin interactions at the molecular level, rather than complete MFAP4 deficiency. This local quality approach allows investigation and treatment of specific MFAP4 functions in fibrosis while preserving other potentially beneficial roles of MFAP4, thereby resolving the contradictory results observed in MFAP4-deficient mouse models
Data Source
AI summary
The present invention relates to a selective targeting agent, which is capable of binding MFAP4 and inhibiting MFAP4-integrin interaction for use in the prevention, alleviation and/or treatment of fibrosis. The invention further comprises compositions comprising said selective targeting agents.